|[March 26, 2012]
eClinical Solutions from BioClinica Accelerate in Europe
NEWTOWN, Pa. --(Business Wire)--
BioClinica®, Inc. (NASDAQ: BIOC), a global provider of
clinical trial management solutions, is quickly becoming the eClinical
provider of choice for European pharmaceutical, medical device,
biotechnology and contract research organizations (CROs). BioClinica's
combination of nimble programing, scalability, ease of use, and high
value are winning the attention of European companies tired of outdated,
slow-moving, cumbersome eClinical systems.
As clinical trials become increasingly global in nature, there is a
growing call for software solutions and services that get trials up and
running faster with less cost. BioClinica is answering this need with a
full range of industry-leading eClinical products, solutions, and
services that help launch and manage studies with a minimum of effort at
a cost far below those typically associated with such high levels of
European-based contracts are not new for BioClinica and have
historically accounted for a significant portion of sales. Clients range
from global pharmaceutical and medical device companies to large and
small CROs. BioClinica's recent European projects include the deployment
of multiple eClinical solutions such as Optimizer, OnPoint CTMS, Trident
IWR, and Express EDC, as well as world-class Data Management services.
With European headquarters in Leiden, The Netherlands, as well as
offices in Lyon, France, BioClinica not only has the technology to
support European customers, but also the dedicated resources on the
continent to support the adoption and deployment of our technology.
BioClinica is also adding skilled positions to support its growing
"European trial sponsors are really seeing the difference compared to
the 'one-size-fits-all' providers," said Peter Benton, BioClinica's
president of eClinical Solutions. "BioClinica specializes in clinical
trial solutions, and our products are built to easily conform to each
individual study rather than forcing the study to fit into a mold. Our
various solutions, such as OnPoint CTMS, Trident IWR, and Express EDC
integrate with each other to help get studies running quickly and
BioClinica's products are recognized for the "Office Smart" capabilities
which arness the power of SharePoint and the Microsoft (News - Alert) Office Suite to
provide study project managers a comprehensive, real-time view into
trial performance. This allows pharmaceutical, biotech, and medical
device manufacturers to leverage their existing investments in Microsoft
Office to better interact with their trial data, reduce the training
timeline, and get studies up and running faster.
BioClinica will demonstrate its eClinical solutions at DIA
EuroMeeting March 26 - 28, 2012 in Copenhagen, Denmark at Booth 138.
Conference attendees are encouraged to contact Martijn Princen at
49.151.2232.1864 or Martijn.Princen@bioclinica.com
to learn ways to streamline their trials and more efficiently manage
Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog,
and on twitter at http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated,
technology-enhanced clinical trial management solutions. BioClinica
supports pharmaceutical and medical device innovation with imaging core
lab, internet image transport, electronic data capture, interactive
voice and web response, clinical trial management and clinical supply
chain design and optimization solutions. BioClinica solutions maximize
efficiency and manageability throughout all phases of the clinical trial
process. With over 20 years of experience and more than 2,000 successful
trials to date, BioClinica has supported the clinical development of
many new medicines from early phase trials through final approval.
BioClinica operates state-of-the-art, regulatory-body-compliant imaging
core labs on two continents, and supports worldwide eClinical and data
management services from offices in the United States, Europe and Asia.
For more information, please visit www.bioclinica.com
Certain matters discussed in this press release are "forward-looking
statements" intended to qualify for the safe harbors from liability
established by the Private Securities Litigation Reform Act of 1995. In
particular, the Company's statements regarding trends in the marketplace
and potential future results are examples of such forward-looking
statements. The forward-looking statements include risks and
uncertainties, including, but not limited to, the consummation and the
successful integration of current and proposed acquisitions, the timing
of projects due to the variability in size, scope and duration of
projects, estimates and guidance made by management with respect to the
Company's financial results, backlog, critical accounting policies,
regulatory delays, clinical study results which lead to reductions or
cancellations of projects, and other factors, including general economic
conditions and regulatory developments, not within the Company's control.
The factors discussed herein and expressed from time to time in the
Company's filings with the Securities and Exchange Commission could
cause actual results and developments to be materially different from
those expressed in or implied by such statements. The
forward-looking statements are made only as of the date of this press
release and the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstance.
You should review the Company's filings, especially risk factors
contained in the Form 10-K and the recent Form 10-Q.
[ Back To SIP Trunking Home's Homepage ]